Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Edwards Lifesciences yesterday released financial strategies and guidance for the fiscal year 2016, raising expectations for the transcatheter heart valve market as a whole, as well as its stake in it over the coming years.
The company upped its estimation for the global TAVR market opportunity to $5 billion by 2021. That number is up from an earlier estimate of over $3 billion by 2019, Leerink Partners’ Danielle Antalffy wrote in a letter to investors. Read more
Analogic said yesterday it may face a $15 million settlement with the U.S. gov’t over a foreign corruption investigation, and released 1st quarter 2016 earnings that missed on forecasted EPS and rev, but saw shares stay strong.
The Peabody, Mass.-based company said the SEC rejected a $1.6 million settlement it made in September over an investigation from 2011 involving its subsidiary BK Medical, and it could now face up to $15 million in combined payments from the Department of Justice and SEC. Read more
NeuroSigma Systems today released preliminary data from a trial of its Monarch trigeminal nerve stimulation system designed to treat combat veterans with traumatic brain injuries, citing improvements in memory, anxiety and brain activity.
The results were presented at the North American Neuromodulation Society’s meeting in Las Vegas, the company said. Read more